Low BDNF is associated with cognitive impairments in patients with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 29, Issue , 2016, Pages 66-71

  Wang, Yu ^a   Liu, Hong ^b   Zhang, Ben Shu ^a   Soares, Jair C ^c   Zhang, Xiang Yang ^c,d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b CHANGZHI MEDICAL COLLEGE   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Brain derived neurotrophic factor; Cognition; Parkinson disease; Serum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ARTICLE; ATTENTION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; LANGUAGE DEVELOPMENT; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR PERFORMANCE; NEUROLOGIC DISEASE ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; ANALYSIS OF VARIANCE; BLOOD; COMPLICATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; REGRESSION ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BRAIN-DERIVED NEUROTROPHIC FACTOR; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REGRESSION ANALYSIS;

EID: 84969975067     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.05.023     Document Type: Article

References (30)

1. [1] Robbins, T.W., Cools, R., Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov. Disord. 29:5 (2014), 597–607.
2. [2] Yarnall, A.J., Breen, D.P., Duncan, G.W., Khoo, T.K., Coleman, S.Y., Firbank, M.J., et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82:4 (2014), 308–316.
3. [3] Aarsland, D., Brønnick, K., Fladby, T., Mild cognitive impairment in Parkinson's disease. Curr. Neurol. Neurosci. Rep. 11:4 (2011), 371–378.
4. [4] Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112 (2003), 257–269.
5. [5] Leal, G., Afonso, P.M., Salazar, I.L., Duarte, C.B., Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 1621 (2015), 82–101.
6. [6] Heldt, S.A., Stanek, L., Chhatwal, J.P., Ressler, K.J., Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol. Psychiatry 12:7 (2007), 656–670.
7. [7] Komulainen, P., Pedersen, M., Hänninen, T., Bruunsgaard, H., Lakka, T.A., Kivipelto, M., et al. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol. Learn Mem. 90:4 (2008), 596–603.
8. [8] Zhang, X.Y., Liang, J., Chen da, C., Xiu, M.H., Yang, F.D., Kosten, T.A., et al. Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia. Psychopharmacology 222:2 (2012), 277–284.
9. [9] Howells, D.W., Porritt, M.J., Wong, J.Y., Batchelor, P.E., Kalnins, R., Hughes, A.J., et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. Neurol. 166 (2000), 127–135.
10. [10] Scalzo, P., Kümmer, A., Bretas, T.L., Cardoso, F., Teixeira, A.L., Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J. Neurology 257:4 (2010), 540–545.
11. [11] Gyárfás, T., Knuuttila, J., Lindholm, P., Rantamäki, T., Castrén, E., Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol. Neurobiol. 30 (2010), 361–368.
12. [12] Leverenz, J.B., Watson, G.S., Shofer, J., Zabetian, C.P., Zhang, J., Montine, T.J., Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Park. Relat. Disord. 1 (2011), 61–64.
13. [13] Costa, A., Peppe, A., Carlesimo, G.A., Zabberoni, S., Scalici, F., Caltagirone, C., et al. Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. Front. Behav. Neurosci. 9 (2015), 253–261.
14. [14] Foltynie, T., Lewis, S.G., Goldberg, T.E., Blackwell, A.D., Kolachana, B.S., Weinberger, D.R., et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J. Neurol. 252 (2005), 833–838.
15. [15] Guerini, F.R., Beghi, E., Riboldazzi, G., Zangaglia, R., Pianezzola, C., Bono, G., et al. BDNF Val66Met polymorphism is associated with cognitive impairment in italian patients with Parkinson's disease. Eur. J. Neurol. 16 (2009), 1240–1245.
16. [16] Białecka, M., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E.J., Honczarenko, K., et al. BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease. Neurosci. Lett. 561 (2014), 86–90.
17. [17] Angelucci, F., Peppe, A., Carlesimo, G.A., Serafini, F., Zabberoni, S., Barban, F., et al. A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. Front. Hum. Neurosci., 9, 2015, 130.
18. [18] Randolph, C., Tierney, M.C., Mohr, E., Chase, T.N., The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J. Clin. Exp. Neuropsychol. 20 (1998), 310–319.
19. [19] Zhang, B.H., Tan, Y.L., Zhang, W.F., Wang, Z.R., Yang, G.G., Shi, C., et al. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a screening test in Chinese: reliability and validity. Chin. Ment. Health J. 28 (2009), 865–869.
20. [20] Ventriglia, M., Zanardini, R., Bonomini, C., Zanetti, O., Volpe, D., Pasqualetti, P., et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed. Res. Int., 2013, 2013, 901082.
21. [21] Mocchetti, I., Bachis, A., Nosheny, R.L., Tanda, G., Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons. Neurotox. Res. 2 (2007), 135–143.
22. [22] Levivier, M., Przedborski, S., Bencsics, C., Kang, U.J., Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 15 (1995), 7810–7820.
23. [23] Gajewski, P.D., Hengstler, J.G., Golka, K., Falkenstein, M., Beste, C., The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. Neurobiol. Aging 32 (2011), 2327.e7–2327.e19.
24. [24] Gratwicke, J., Jahanshahi, M., Foltynie, T., Parkinson's disease dementia: a neural networks perspective. Brain 138:Pt 6 (2015), 1454–1476.
25. [25] He, Y.Y., Zhang, X.Y., Yung, W.H., Zhu, J.N., Wang, J.J., Role of BDNF in central motor structures and motor diseases. Mol. Neurobiol. 48 (2013), 783–793.
26. [26] Meis, S., Endres, T., Lessmann, V., Postsynaptic BDNF signalling regulates long-term potentiation at thalamo-amygdala afferents. J. Physiol. 590:Pt 1 (2012), 193–208.
27. [27] Jahanshahi, M., Jones, C.R., Zijlmans, J., Katzenschlager, R., Lee, L., Quinn, N., et al. Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain 133:Pt 3 (2010), 727–745.
28. [28] Cools, R., Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci. Biobehav. Rev. 30 (2006), 1–23.
29. [29] Narita, M., Aoki, K., Takagi, M., Yajima, Y., Suzuki, T., Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience 119:3 (2003), 767–775.
30. [30] Rana, A.Q., Ahmed, U.S., Chaudry, Z.M., Vasan, S., Parkinson's disease: a review of non-motorsymptoms. Expert. Rev. Neurother. 15 (2015), 549–562.